Theranostics 2020; 10(7):2918-2929. doi:10.7150/thno.41077 This issue Cite

Research Paper

One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy

Xiaojuan Zhang1, Chuanchuan He1, Xiaoguang Liu1, Yan Chen1, Pengxuan Zhao1, Chen Chen1, Ruicong Yan1, Minsi Li1, Ting Fan1, Bouhari Altine2,3, Tan Yang1, Yao Lu1, Robert J. Lee4, Yongkang Gai2,3✉, Guangya Xiang1✉

1. School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
2. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
3. Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China
4. Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, OH 43210, USA

Citation:
Zhang X, He C, Liu X, Chen Y, Zhao P, Chen C, Yan R, Li M, Fan T, Altine B, Yang T, Lu Y, Lee RJ, Gai Y, Xiang G. One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. Theranostics 2020; 10(7):2918-2929. doi:10.7150/thno.41077. https://www.thno.org/v10p2918.htm
Other styles

File import instruction

Abstract

Graphic abstract

Nanoparticle formulations have proven effective for cisplatin delivery. However, the development of a versatile nanoplatform for cisplatin-based combination cancer therapies still remains a great challenge.

Methods: In this study, we developed a one-pot synthesis method for a microporous organosilica shell-coated cisplatin nanoplatform using a reverse microemulsion method, and explored its application in co-delivering acriflavine (ACF) for inhibiting hypoxia-inducible factor-1 (HIF-1).

Results: The resulting nanoparticles were tunable, and they could be optimized to a monodisperse population of particles in the desired size range (40-50 nm). In addition, organic mPEG2000-silane and tetrasulfide bond-bridged organosilica were integrated into the surface and silica matrix of nanoparticles for prolonged blood circulation and tumor-selective glutathione-responsive degradation, respectively. After reaching the tumor sites, cisplatin induced cancer cell death and activated HIF-1 pathways, resulting in acquired drug resistance and tumor metastasis. To address this issue, ACF was co-loaded with cisplatin to prevent the formation of HIF-1α/β dimers and suppress HIF-1 function. Hence, the efficacy of cisplatin was improved, and cancer metastasis was inhibited.

Conclusion: Both in vitro and in vivo results suggested that this core-shell nanostructured cisplatin delivery system represented a highly efficacious and promising nanoplatform for the synergistic delivery of combination therapies involving cisplatin.

Keywords: cisplatin, nanoparticle, HIF-1, acriflavine, combination therapy


Citation styles

APA
Zhang, X., He, C., Liu, X., Chen, Y., Zhao, P., Chen, C., Yan, R., Li, M., Fan, T., Altine, B., Yang, T., Lu, Y., Lee, R.J., Gai, Y., Xiang, G. (2020). One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. Theranostics, 10(7), 2918-2929. https://doi.org/10.7150/thno.41077.

ACS
Zhang, X.; He, C.; Liu, X.; Chen, Y.; Zhao, P.; Chen, C.; Yan, R.; Li, M.; Fan, T.; Altine, B.; Yang, T.; Lu, Y.; Lee, R.J.; Gai, Y.; Xiang, G. One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. Theranostics 2020, 10 (7), 2918-2929. DOI: 10.7150/thno.41077.

NLM
Zhang X, He C, Liu X, Chen Y, Zhao P, Chen C, Yan R, Li M, Fan T, Altine B, Yang T, Lu Y, Lee RJ, Gai Y, Xiang G. One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. Theranostics 2020; 10(7):2918-2929. doi:10.7150/thno.41077. https://www.thno.org/v10p2918.htm

CSE
Zhang X, He C, Liu X, Chen Y, Zhao P, Chen C, Yan R, Li M, Fan T, Altine B, Yang T, Lu Y, Lee RJ, Gai Y, Xiang G. 2020. One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. Theranostics. 10(7):2918-2929.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image